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The cytochromes P450 are a multigene super-family of
enzymes, existing as multiple forms, which metabolise a wide
variety of xenobiotics and endogenous compounds including
steroid hormones and arachidonic acid (Gonzalez, 1990;
Nebert & Gonzalez, 1987; Nebert et al., 1989; Fitzpatrick &
Murphy, 1988). This group of enzymes has a central role in
activating and detoxifying chemical carcinogens and anti-
cancer drugs (Guengerich, 1988). The major forms of cyto-
chrome P450 involved in xenobiotic metabolism (cytochrome
P450 families I, II and III) are predominantly found in liver.
Specific forms of cytochrome P450 have been identified in a
variety of extra hepatic tissues including lung, kidney, small
intestine and steroidogenic tissues.
The expression of cytochromes P450 and their associated
mono-oxygenase activities have been extensively studied in
chemically induced liver tumours in animals (Buchmann et
al., 1985; Roomi et al., 1985; Stout & Becker, 1986) and
cytochrome P450 has generally been found to be reduced in
hepatic tumours compared with adjacent non-neoplastic liver.
However, there have been few studies of cytochrome P450
expression or activity in human tumours.
In this study we have investigated the expression of a
major family of cytochrome P450, cytochrome P450IA, in
human breast carcinoma. Two closely related subfamilies (or
forms) of cytochrome P45OIA, cytochrome P450IA1 and
cytochrome P450IA2 have been identified in rat and similar
forms occur in man (loannides & Parke, 1990). The murine
monoclonal antibody RM3 used in this study recognises rat
cytochrome P450IA1 and not rat cytochrome P450IA2 and
recognises a single band on immunoblots of human liver.
However, it is not known which subfamily member(s) of the
cytochrome P450IA family is recognised by RM3 in man,
therefore the protein recognised by RM3 in this study is
referred to by the gene family name, cytochrome P45OIA. We
have demonstrated for the first time the constitutive expres-
sion of a specific form of cytochrome P450 in breast cancer.
Breast carcinomas of no special type were obtained from
breast biopsies submitted to the Department of Pathology,
University of Aberdeen for diagnostic purposes. All tumours
were fixed in 10% neutral buffered formalin and routinely
processed to paraffin wax and blocks were selected for study
which contained both tumour and non-neoplastic breast tis-
sue.
Cytochrome P450IA expression was demonstrated immuno-
cytochemically with a murine monoclonal antibody (RM3),
which recognises cytochrome P450IA. The monoclonal
antibody RM3 was produced in mice using highly purified
rat liver cytochrome P450IA1 as described elsewhere (Barnes
et al., 1987). Briefly pure rat hepatic cytochrome P450IAI
was used to immunise female BALB/c mice and after the
final immunisation hybridomas were formed by fusing mouse
spleen cells with a murine myeloma cell line (Ag8.653).
Monoclonal antibodies to cytochrome P450IA were then
selected by enzyme linked immunoabsorbent and immuno-
blot procedures. The antibody (RM3) recognises rat hepatic
cytochrome P45OIAI and not rat hepatic cytochrome
P450IA2 and recognises a single protein band on immuno-
blots of human liver microsomes.
Formalin fixed wax embedded sections of breast car-
cinomas were dewaxed in xylene, rehydrated in descending
concentrations of alcohol and labelled with RM3 without
prior proteolytic enzyme digestion as previously described
(Murray et al., 1987a). Binding of RM3 was identified by an
immunoperoxidase technique using peroxidase conjugated
rabbit anti-mouse immunoglobulin as the secondary antibody
and demonstrating sites of bound peroxidase with diamino-
benzidine as the peroxidase substrate (Murray et al., 1987a).
Replacing the primary layer antibody (RM3) with 0.05 M
Tris-HCI buffered saline pH 7.6 acted as a negative control.
Immunostaining ofeach tumour was assessed qualitatively by
light microscopy of each section on a two point scale i.e.
positive immunostaining or negative immunostaining.
Breast tumours were graded using the criteria of Bloom
and Richardson, 1957 as modified by Elston, 1984. Oestrogen
receptors in the breast carcinomas were assayed using a
radiometric assay and tumours were considered positive
when the receptor level was greater than lOfmolmg-' pro-
tein. Information regarding smoking habits and drug history
was obtained from study of patients notes. Statistical correla-
tions were examined with the chi-squared test.
Fifty-four examples of primary operable breast carcinoma
of no special type were studied from 54 patients. The age
range of the patients was 31-80 and there were eight grade
1, 30 grade 2 and 16 grade 3 tumours. There were 35
oestrogen receptor positive tumours and 10 oestrogen recep-
tor negative tumours (oestrogen receptor assay not per-
formed in nine tumours). There were 39 non-smokers and 14
current smokers (information not available for one patient)
and no patients were receiving drugs which were known to
induce cytochrome P450.
Twenty-one of the 54 tumours studied (39%) showed posi-
tive imrmiunoreactivity for cytochrome P4SOIA (Figures 1 and
2). The immunostaining was present within the cytoplasm of
the tumour cells and there were no nuclear staining. The
immunostaining was present only in areas of invasive car-
cinoma, and there was no immunoreactivity of tumour cells
or foci of ductal carcinoma in situ. In addition there was no
staining of adjacent normal breast epithelium (Figure 3),
areas of epithelial hyperplasia, chronic inflammatory cells
associated with tumour cells, mast cells and connective tissue.
Specific staining of tumour cells was abolished when the anti
cytochrome P450 antibody was omitted from the immuno-
cytochemical procedure.
There was no correlation between cytochrome P450 expres-
sion, tumour grade (three grades: chi-squared = 3.03,
P >0.1), oestrogen receptor status (two categories, positive
and negative: chi squared = 0.2, P >0.1) or smoker: chi
squared = 0.2, P >0.1).
This report describes the constitutive expression of a
specific form of cytochrome P450, cytochrome P45OIA, in
human breast cancer. Cytochrome P450XIXA1 (P450
aromatase) has previously been identified in breast cancer
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(Lipton et al., 1987) although it has also been identified in
non-neoplastic breast tissue (Newton et al., 1986) in contrast
with the current report ofcytochrome P4501A which appears
to be present only in malignant tumour cells. Cytochrome
P4501A is a major family of cytochrome P450 consisting of
two members, cytochrome P4501A1 and cytochrome P450IA2,
and the monoclonal antibody used in this study recognises
rat cytochrome P4501A1 and not rat cytochrome P4540IA2
and recognises a single band on immunoblots of human liver
3:~ ~ ~ ~
Figure 1 There is cytoplasmic staining of tumour cells when
immunostained with anti-cytochrome P4501A antibody. Grade 2
carcinoma. x 320.
Figure 2 Immunostaining is abolished when the anti-cytochrome
P4501A antibody is omitted. Grade 2 carcinoma, haematoxylin
counterstain. x 320.
Figure 3 There is no immunostaining for cytochrome P4501A of
non-neoplastic breast tissue adjacent to a breast cancer displaying
positive cytochrome P4501A immunoreactivity. Haematoxylin
counterstain. x 320.
microsomes, although it is not yet known which human
cytochrome P4501A family member it recognises. The
monoclonal antibody RM3 does not recognise purified
human cytochrome P450hA7 (a member of the cytochrome
P450IIIA family) or P45OhB (a member of the P450IIC
family) (manuscript in preparation).
Cytochrome P4501A expression was demonstrated using a
specific and sensitive technique which has the spatial resolu-
tion to identify even a few cells expressing cytochrome
P450IA. Proteolytic enzyme digestion was not performed
prior to immunostaining as we have shown that cytochrome
P450 immunoreactivity is abolished by proteolytic enzyme
activity (Murray et al., 1987a). Cytochrome P4501A activity
was identified only in tumour cells and 39% of tumours
displayed expression of cytochrome P4501A. The expression
of cytochrome P4501A was present only in areas of invasive
tumour, there was no expression of cytochrome P4501A in
foci of ductal carcinoma in situ or non-neoplastic breast
epithelium. The expression of cytochrome P450IA did not
appear to depend on the degree of differentiation of the
tumour since there was no correlation with the tumour grade.
Similarly there was no correlation between cytochrome
P4501A expression and smoking habits although smoking
may induce expression of this family of cytochrome P450 in
liver (loannides & Parke, 1990) and extrahepatic tissue.
There have been few studies ofcytochrome P450 in human
tumours and this is the first report to describe the consti-
tutive expression of a specific form of cytochrome P450 in a
tumour when there is no expression of cytochrome P450 in
the surrounding non-tumour tissue. These findings contrast
with the decreased expression of cytochrome P450 observed
in chemically induced experimental liver tumours (Buchmann
et al., 1985; Roomi et al., 1985; Stout & Becker, 1986) and
similarly two previous studies of small numbers ofhepatocel-
lular carcinomas have shown generally decreased expression
of cytochrome P450IIIA in tumour cells (El Mouelhi et al.,
1987; Murray et al., 1987b) compared with surrounding non-
tumour liver which has a high concentration of cytochrome
P450IIIA. In addition, cytochrome P45OIA1 expression has
been described in lung cancers from cigarette smokers andCYTOCHROME P450 IN BREAST CANCER 1023
there was also expression of cytochrome P4501A1 in non-
tumour lung tissue (McLemore et al., 1990).
Cytochrome P4501A is a major form of cytochrome P450
and one of its functions is to catalyse the conversion of
17-f-oestradiol (oestrogen) to 2-hydroxyoestradiol which is
essentially devoid of biological activity (Graham et al., 1988).
Induction of expression of this form of cytochrome P450
activity in a human breast cancer line has been shown to
have a marked anti-oestrogenic effect and thus inhibit growth
of tumour cells (Gierthy et al., 1988; Schneider et al., 1984).
Therefore the presence of cytochrome P4501A in breast
cancers could act as a novel anti-oestrogen due to the intra-
tumour metabolism of oestrogen. Thus the expression of
cytochrome P4501A in breast cancer may have implications
for the treatment of those breast cancers whose growth is
oestrogen dependent. The presence of cytochrome P450IA
might potentially be used as a marker of a group of breast
cancers which will respond to a particular type of therapy.
Part of this work was funded by the Scottish Home and Health
Department. RJW was an SERC-CASE student with Wellcome
Research Ltd.
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